Celebrating India’s independence, enterprise and progress
news

Chandigarh University Researchers Develop an Economical Device for Accurate Drug Absorption Studies; to Help in Reducing Cost of Medicines by 40%

Jul 28, 2026 · Source: cision
Chandigarh University Researchers Develop an Economical Device for Accurate Drug Absorption Studies; to Help in Reducing Cost of Medicines by 40%

Chandigarh University researchers get patent for an energy-efficient, economical device for accurate drug absorption studies

CHANDIGARH, India, July 28, 2026 -- A team of researchers at Chandigarh University has developed an innovative laboratory device that could significantly improve the way oral medicines are tested during development, enabling more accurate, reliable and cost-effective drug absorption studies that can ultimately support the development of safer and more effective medicines. By addressing several long-standing limitations in conventional drug absorption equipment, the innovation enables researchers to generate more dependable experimental data while reducing the likelihood of failed studies, repeated experiments and unnecessary research costs. The improved version of the apparatus also reduces the size and complexity of the conventional equipment, resulting in a 40 per cent reduction in operational costs and making a low-cost version of the device available for pharmaceutical research and routine laboratory use.

Research Scholar, Prof. Dr. Satbir Singh Sehgal while holding the patent certificate ‘Improved Oral Drug Absorption Study Cell’ granted by the Indian Patent Office

Recognizing the novelty and practical significance of the innovation, the Indian Patent Office has granted the Chandigarh University researchers a patent for their invention titled 'Improved Oral Drug Absorption Study Cell'. The innovation, developed by Chandigarh University researchers, Prof. (Dr.) S.S. Sehgal and Prof. (Dr.) Manish Goswami (former professor at University Institute of Pharmaceutical Sciences), Chandigarh University, has been granted a patent by the Indian Patent Office for its novel design. The patented device introduces engineering improvements that overcome several limitations of the conventional drug absorption apparatus while remaining simple to manufacture, economical to operate and suitable for routine laboratory use.

The reliable drug absorption studies form the foundation of oral medicine development, helping scientists determine whether a medicine administered orally can efficiently cross the intestinal barrier and enter the bloodstream before it progresses to advanced stages of research. More accurate laboratory data allows researchers to optimise formulations much earlier in the development cycle, reducing uncertainty before medicines move to expensive pre-clinical and clinical evaluation while strengthening confidence in pharmaceutical research.

Sharing details and significance of the innovation, Prof. (Dr.) S.S. Sehgal said, "Drug absorption studies are among the most important stages in oral drug development because they help scientists understand how efficiently a medicine is likely to be absorbed before it progresses to advanced stages of research. The conventional drug absorption equipment offer very limited space, forcing researchers to fold the everted intestinal tissue inside the chamber. This places unnecessary stress on the tissue, affects its natural positioning and can result in variability into the drug experimental observations. In many cases, tissue damage or improper placement can even result in experimental failure that forces researchers to repeat the study and increase both development time and research costs."

Prof. Sehgal added, "Instead of altering the testing methodology, we redesigned the apparatus to address the limitations of conventional systems. By introducing an extended side arm, our equipment allows the tissue to remain in a natural U-shaped position helping in proper drug absorption to occur under consistent conditions. Along with improved temperature uniformity, better mixing of the drug solution and greater operational stability, the redesigned apparatus helps generate more accurate and reproducible data that can improve the evaluation of oral drug formulations."

Highlighting the broader impact of the invention, Prof. (Dr.) Manish Goswami said, "Scientific progress is often driven by improving the tools researchers use every day. Even relatively small improvements in laboratory equipment can have a significant impact on the quality of research data. By making drug absorption studies more reliable and easier to perform, this innovation can support pharmaceutical scientists in developing better oral formulations and ultimately contribute to medicines that offer greater therapeutic effectiveness for patients."

Elaborating on the improvements, Dr. Manish Goswami said, "Our objective was to improve the reliability of the experiment through a simple yet effective engineering solution. One of the biggest advantages of this innovation is that it minimizes variations during sample collection, making drug absorption studies more reliable and consistent. The device features a compact design built using laboratory-grade materials such as borosilicate and Teflon-coated glass to ensure durability and precision. At the same time, its optimized architecture reduces the overall size of the apparatus, simplifies fabrication and handling, and lowers operational costs by 40 per cent, making it an economical solution for pharmaceutical research. These improvements create more consistent and reproducible experimental conditions, enabling researchers to generate higher-quality data without adding complexity to the procedure."

The innovation is expected to benefit through its application in pharmaceutical industry, drug discovery and development sector, pharmaceutical R&D centres, Contract Research Organizations (CROs), Clinical Research Organizations (CROs), universities and pharmacy colleges, government research laboratories and regulatory testing laboratories where drug absorption studies are routinely carried out for formulation development, pre-clinical research and evaluation of oral medicines.

Apart from improving the experimental accuracy, the redesigned apparatus also reduces operational complexity by eliminating the need for extra heating arrangements. Its simplified design lowers energy requirements, improves laboratory efficiency and reduces overall operating costs, making it suitable for routine use across pharmaceutical laboratories, academic institutions and research organisations.

With oral medicines accounting for the majority of pharmaceutical formulations used worldwide, improvements in early-stage drug absorption studies can strengthen the entire drug development process. By enabling more reliable laboratory testing while reducing time, cost and experimental variability, Chandigarh University's patented innovation has the potential to support faster formulation optimisation, improve pharmaceutical research and contribute to the development of safer, more effective oral medicines for patients across the globe.

About Chandigarh University

Chandigarh University is a NAAC A+ Grade University and QS World Ranked University. This autonomous educational institution is approved by UGC and is located near Chandigarh in the state of Punjab. It is the youngest university in India and the only private university in Punjab to be honoured with A+ Grade by NAAC (National Assessment and Accreditation Council). CU offers more than 109 UG and PG programs in the field of engineering, management, pharmacy, law, architecture, journalism, animation, hotel management, commerce, and others. It has been awarded as The University with Best Placements by WCRC.

Website address: https://www.cuchd.in/

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/chandigarh-university-researchers-develop-an-economical-device-for-accurate-drug-absorption-studies-to-help-in-reducing-cost-of-medicines-by-40-302836315.html

Comments (0)

Login to join the conversation

Login / Register

No comments yet. Be the first to comment!

More to Read

VICTORINOX INDIA WELCOMES ABHAY DEOL AS A FRIEND OF THE BRAND
news
Aug 15, 2026 1 min

VICTORINOX INDIA WELCOMES ABHAY DEOL AS A FRIEND OF THE BRAND

SHARED VALUES. AUTHENTICITY. CHARACTER. MUMBAI, India , Aug. 15, 2026 -- Victorinox India today announced actor Abhay Deol as a Friend of the Brand for its watch portfolio for the coming 18 months . Known for his authenticity, independent spirit and thoughtful approach to life, Deol reflects values that have guided Victorinox for more than 140 years. The association will bring Abhay Deol across Victorinox s watch portfolio, all collections including I.N.O.X., Maverick, Concept One Solar, Air Pro, Dive Pro and Concept One Automatic . Throughout this term, Deol will feature across all media touch touchpoints including digital, outdoor and retail touchpoints, celebrating a shared commitment to character, quality and enduring craftsmanship.

77 DAYS TO GO: 7 WONDERS OF FUTURE CITIES COUNTS DOWN TO START OF VOTING
news
Aug 15, 2026 1 min

77 DAYS TO GO: 7 WONDERS OF FUTURE CITIES COUNTS DOWN TO START OF VOTING

DUBAI, UAE , Aug. 15, 2026 -- 7 Wonders of Future Cities today marks 77 days until global voting begins on www.7wondersfc.com on 31 October 2026. The day, also known as World Cities Day, will be when the public can start choosing amongst the participating cities and developments, to become historically recognised as the leading representatives of the future of urban life. According to Jean-Paul de la Fuente, Chairman of the 7 Wonders of Future Cities campaign, Public participation, global visibility and the status of our recognised brand can transform urban vision into a shared cause, and we are seeing this already with motivating engagement from participating cities and developments from all over the world.

TestMu AI Unveils the Fifth Edition of the TestMu Conference in 2026
news
Aug 14, 2026 1 min

TestMu AI Unveils the Fifth Edition of the TestMu Conference in 2026

The world s largest virtual agentic engineering and quality conference returns with a focus on autonomous quality, agentic workflows, and AI-native testing strategies SAN FRANCISCO and NOIDA, India , Aug. 14, 2026 -- TestMu AI (formerly LambdaTest), the world s first Agentic AI-powered Quality Engineering platform, is excited to unveil the 5th edition of its flagship TestMu Conference, taking place virtually from August 19 21, 2026. This year s event is expected to host over 75,000 developers, builders, and quality engineers from more than 120 countries, making it the world s largest virtual conference dedicated to agentic engineering and quality.

Michael Owen Joins ehamarkets as Global Brand Ambassador
news
Aug 14, 2026 1 min

Michael Owen Joins ehamarkets as Global Brand Ambassador

HONG KONG and NEW YORK , Aug. 14, 2026 -- ehamarkets today announced a global brand partnership with England football legend and 2001 Ballon d Or winner Michael Owen, who has joined the brand as its Global Brand Ambassador. Owen said he was drawn to ehamarkets focus on technology, reliability and a simpler trading experience. I m delighted to join ehamarkets as its Global Brand Ambassador. I like the way ehamarkets uses technology to make trading simpler and more efficient. It s exciting to be part of a brand that is building a modern trading experience for people around the world.

RemotePeople Completes 2026 SOC 2 Type II Audit Across Security, Availability, and Confidentiality
news
Aug 14, 2026 1 min

RemotePeople Completes 2026 SOC 2 Type II Audit Across Security, Availability, and Confidentiality

The New York-headquartered global Employer of Record renews its SOC 2 Type II attestation for a full 12-month period, adding to its ISO 27001 and GDPR certifications and its recent A+ platform security rating from Astra Security. NEW YORK , Aug. 14, 2026 -- RemotePeople, a global provider of Employer of Record (EOR), payroll, and recruitment services operating in more than 150 countries, today announced the successful completion of its 2026 SOC 2 Type II audit , covering the Security, Availability, and Confidentiality Trust Service Criteria. The independent examination was performed by INTERCERT CPA LLC in accordance with AICPA SSAE 21 attestation standards and covered a continuous 12-month observation period from May 31, 2025 to May 30, 2026.

Bybit TradFi Perpetuals Extend 24/7 Exposure to Over 200 Global Equities and Pre-IPO Assets
news
Aug 14, 2026 1 min

Bybit TradFi Perpetuals Extend 24/7 Exposure to Over 200 Global Equities and Pre-IPO Assets

DUBAI, UAE , Aug. 14, 2026 -- Bybit , the world s second-largest cryptocurrency exchange by trading volume, is pleased to announce TradFi Perpetual Contracts now offer over 200 curated TradFi-themed listings , marking one of the highest quality coverage of TradFi derivatives exposure available on a crypto-native platform. The lineup now spans equities, ETFs, precious metals, indices, and oil, with coverage extending across premium US, Hong Kong, South Korean and other equities markets.

FERRERO GROUP TO ACQUIRE PURELY ELIZABETH, A LEADING U.S. MODERN WELLNESS BRAND
news
Aug 14, 2026 1 min

FERRERO GROUP TO ACQUIRE PURELY ELIZABETH, A LEADING U.S. MODERN WELLNESS BRAND

LUXEMBOURG and BOULDER, Colo. , Aug. 14, 2026 -- Ferrero Group today announced it has signed an agreement to acquire Purely Elizabeth, the high-growth modern wellness brand and a leading better-for-you food company based in the U.S. The acquisition further enhances Ferrero s relevance at the American breakfast table with Purely Elizabeth joining its portfolio. Following closing, Ferrero intends to support Purely Elizabeth s next phase of growth through continued product innovation, operational capabilities and expanded distribution, helping the brand reach more consumers while preserving its distinct identity and commitment to quality.

Deeper Insights, Better Analytics: Bybit Options Close the Data Gap Between Retail and Institutional Traders
news
Aug 14, 2026 1 min

Deeper Insights, Better Analytics: Bybit Options Close the Data Gap Between Retail and Institutional Traders

DUBAI, UAE , Aug. 14, 2026 -- Bybit , the world s second-largest cryptocurrency exchange by trading volume, announced a major upgrade to its Options Data section, introducing a suite of institutional-grade analytics to provide traders with a clearer view of volatility, positioning, and market structure. The redesigned page integrates institutional-grade analytics with a cleaner, more accessible interface for all users. Options trading has been gaining popularity among digital asset derivatives traders, as they increasingly move beyond simple long or short positions to alternative strategies that account for volatility, time decay, and risk management. Options give traders the right, but not the obligation, to buy or sell an asset at a set price before a set date.